目的 观察安罗替尼联合贝伐珠单抗治疗复发转移性宫颈癌的临床疗效。方法 选取收治的120例复发转移性宫颈癌患者，用随机数字表法分为对照组和联合组，每组60例。对照组给予贝伐珠单抗及常规化疗，联合组在对照组治疗的基础上给予安罗替尼治疗。比较2组患者血清细胞角蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1，CYFRA21-1)、肿瘤特异性生长因子(tumor specific growth factor，TSGF)、鳞状细胞癌抗原(squamous cell carcinoma antigen，SCC-Ag)、免疫指标(CD3+、CD4+和CD8+)、临床症状(输尿管梗阻、阴道感染和阴道流血)改善情况、临床疗效及不良反应发生情况。结果 与治疗前比较，2组治疗后血清CYFRA21-1、TSGF、SCC-Ag水平及CD8+水平均明显降低(P<0。05)，且联合组低于对照组(P<0。05);治疗后2组CD3+及CD4+水平均明显升高(P<0。05)，且联合组高于对照组(P<0。05);对照组治疗前后输尿管梗阻、阴道感染及阴道流血的发生率比较差异无统计学意义(P>0。05)，联合组治疗后输尿管梗阻、阴道感染及阴道流血的发生率均明显低于治疗前，且低于同期对照组(P<0。05);联合组的临床控制率(68。33%)明显高于对照组(48。33%)，P<0。05;2组患者血压升高、胃肠道不良反应、血小板降低及中性粒细胞减少等不良反应的发生率比较差异无统计学意义(P>0。05)。结论 安罗替尼联合贝伐珠单抗治疗复发转移性宫颈癌患者可有效调节免疫功能，改善临床症状，降低CYFRA21-1、TSGF及SCC-Ag水平，且安全性高。
Effect of anlotinib combined with bevacizumab in the treatment of patients with recurrent and metastatic cervical cancer
Objective To observe the clinical efficacy of anlotinib combined with bevacizumab in the treatment of patients with recurrent and metastatic cervical cancer.Methods 120 patients with recurrent and metastatic cervical cancer were selected and randomly divided into a reference group and a combined group by using a random number table method,with 60 cases in each group.The patients in the reference group were given bevacizumab and conventional chemotherapy,while the patients in the combined group were given anlotinib on the basis of the reference group.The serum levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1),tumor-specific growth factor(TSGF),squamous cell carcinoma antigen(SCC-Ag),and immune indexes(CD3+,CD4+,CD8+),the improvement of clinical symptoms(ureteral obstruction,vaginal infection,and vaginal bleeding),the clinical efficacy and the occurrence of adverse reactions were compared between the 2 groups.Results Compared with before treatment,the serum CYFRA21-1,TSGF,SCC-Ag and CD8+ levels in both groups were greatly decreased after treatment(P<0.05),and compared with the reference group,the combined group were much lower(P<0.05).Compared with before treatment,the levels of CD3+ and CD4+ in both groups after treatment were greatly increased(P<0.05),and compared with the reference group,the combined group were much higher(P<0.05).There was no significant difference in the incidence of ureteral obstruction,vaginal infection,and vaginal bleeding in the reference group before and after treatment(P>0.05).After treatment,the above indicators in the combined group were much lower than those before treatment,and were lower than those in the reference group(P<0.05).The clinical control rate of the combined group(68.33%)was significantly higher than that of the control group(48.33%)(P<0.05).There was no significant difference in the incidence of adverse reactions such as increased blood pressure,gastrointestinal adverse reactions,thrombocytopenia and neutropenia between the 2 groups(P>0.05).Conclusion Anlotinib combined with bevacizumab in the treatment of patients with recurrent and metastatic cervical cancer can effectively regulate immune function,improve clinical symptoms,and reduce the levels of CYFRA21-1,TSGF and SCC-Ag.
bevacizumabanlotinibrecurrent and metastatic cervical cancer
NETL
NSTL
万方数据
维普
